Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 May 2022
Robert Frater
The research efforts in the Department of Cardiothoracic Surgery in the Faculty of Health Sciences, UFS, have come a long way since the establishment of a homograft bank, animal research, and laboratory-based research on cardioplegia by Prof Hannes Meyer in the 1980s

Several world-class scientists and academics in the field of cardiovascular research will converge at the University of the Free State (UFS) on Thursday (5 May 2022) for a one-day hybrid conference to explore and celebrate the massive strides made in this critical field at the UFS Robert W M Frater Cardiovascular Research Centre.

The research efforts in the Department of Cardiothoracic Surgery in the Faculty of Health Sciences, UFS, have come a long way since the establishment of a homograft bank, animal research, and laboratory-based research on cardioplegia by Prof Hannes Meyer in the 1980s. Renewed interest in 2004 under the leadership of Prof Francis E Smit culminated in the establishment of the Robert W M Frater Cardiovascular Research Centre (the Frater Centre) in 2015. This was made possible through donor funding, especially by Dr Robert W M Frater MD PhD (honoris causa, UFS), a South Africa-born New York-based cardiothoracic surgeon, researcher and innovator as infrastructure and project support by the UFS.

The vision of the Frater Centre is to be a leading cardiovascular research institution in South Africa and sub-Saharan Africa. It provides an interdisciplinary training and research platform for scientists and clinicians from different backgrounds to develop as researchers and collaborators in cardiovascular and thoracic surgery and related domains. Activities are focused on the development of African solutions for African problems.

Three main divisions
The Frater Celebration day will highlight the achievements made thus far in a hybrid format in four sessions, which can be attended on a virtual platform or in person. The centre’s local and international collaborators will participate in the programme, and Dr Ronnie van der Merwe, the Group CEO of Mediclinic International, is the guest of honour.

The Frater Centre consists of three main divisions, all of which will form part of the focus of the conference programme in various forms during the day:

1) The Clinical Research Division addresses cardiovascular disease on a broad front, ranging from population and prevalence studies, healthcare solutions and clinical outcomes studies in a specific South African and African context.

2) The Research, Development and Commercialisation division is divided into Tissue Engineering and Cell Biology, Tissue Banking and Large Animal studies, and bioengineering to develop African solutions and technology within these domains.

3) The Simulation Programme provides an integrated interdisciplinary platform for the education and training of individuals and teams in cardiovascular, thoracic, anaesthetic, perfusion technology and related nursing fields in a state-of-the-art simulation unit. The research centre is developing a unique and leading programme and systems in this field. This endeavour is also developing IT models for training, evaluation and research.

The Frater Centre and 4IR
The Centre is firmly established in the fourth industrial revolution. It is new technology-driven, creating new IT platforms and boasts extensive interdisciplinary projects at the biomedical sector's local, national, and international levels.

It is essential to note that the extensive and successful collaboration within the Frater Centre not only exists on institutional level but also nationally and internationally. These collaborators assist, mentor, direct and contribute to the research activities.

Click: Link to the event
Event programme



News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept